Cancer Research UK Edinburgh Centre

Olaparib approved in Scotland as new ovarian cancer treatment

Clinical trial with key contributions from Cancer Research UK Edinburgh Centre clinicians leads to approval of cancer drug olaparib as new ovarian cancer treatment in Scotland: December 2019

Professor Charlie Gourley - Chair of Medical Oncology and Honorary Consultant in Medical Oncology. Clinical Director CRUK Edinburgh Centre; Director, Nicola Murray Centre for Ovarian Cancer Research.
Professor Charlie Gourley - Chair of Medical Oncology and Honorary Consultant in Medical Oncology. Clinical Director CRUK Edinburgh Centre; Director, Nicola Murray Centre for Ovarian Cancer Research.

More than 350 women die from ovarian cancer in Scotland each year. Professor Charlie Gourley from the CRUK Edinburgh Centre is the UK lead of the pivotal SOLO-1 clinical trial that helped to approve olaparib as maintenance treatment for patients with advanced ovarian cancer and brought new hope to ovarian cancer patients.

Read the story on BBC website  Read the story on STV website

Related Links: